Clinical Trial Update: To Determine the Efficacy of Neurokinin 1 Receptor Antagonist as a Therapeutic Tool Against Cytokine Storm and Respiratory Failure in Covid-19 Patients [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is investigating a neurokinin-1 receptor antagonist as a therapy for cytokine storm and respiratory failure in COVID-19 patients; statu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytokine Storm
• Respiratory Failure

Drugs mentioned

• neurokinin-1 receptor antagonist

Snippet

Sponsor: Prof. Dr. Fridoon Jawad Ahmad | Conditions: Neurokinin 1 Receptor, Substance P, Respiratory Illness, Inflammation, Covid-19, Coronavirus | Phase 3 | Status: UNKNOWN